메뉴 건너뛰기




Volumn 9, Issue 10, 2004, Pages 430-431

Ligand efficiency: A useful metric for lead selection

Author keywords

Drug Discovery; Drugs; Lead optimization; Ligands; Pharmaceutical Science; Potency; Techniques Methods

Indexed keywords

FUNCTIONAL GROUP; LEAD;

EID: 1942453243     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(04)03069-7     Document Type: Note
Times cited : (1670)

References (11)
  • 2
    • 0035324944 scopus 로고    scopus 로고
    • Molecular complexity and its impact on the probability of finding leads for drug discovery
    • Hann M., et al. Molecular complexity and its impact on the probability of finding leads for drug discovery. J. Chem. Inf. Comput. Sci. 41:2001;856-864.
    • (2001) J. Chem. Inf. Comput. Sci. , vol.41 , pp. 856-864
    • Hann, M.1
  • 3
    • 0033576601 scopus 로고    scopus 로고
    • The design of leadlike combinatorial libraries
    • Teague S., et al. The design of leadlike combinatorial libraries. Angew Chem. Int. Ed. Engl. 24:1999;3743-3748.
    • (1999) Angew Chem. Int. Ed. Engl. , vol.24 , pp. 3743-3748
    • Teague, S.1
  • 4
    • 0035438391 scopus 로고    scopus 로고
    • Is there a difference between leads and drugs?
    • Oprea T., et al. Is there a difference between leads and drugs? J. Chem. Inf. Comput. Sci. 41:2001;1308-1315.
    • (2001) J. Chem. Inf. Comput. Sci. , vol.41 , pp. 1308-1315
    • Oprea, T.1
  • 5
    • 0034461768 scopus 로고    scopus 로고
    • Drug-like properties and the causes of poor solubility and poor permeability
    • Lipinski C. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods. 44:2000;235-249.
    • (2000) J. Pharmacol. Toxicol. Methods , vol.44 , pp. 235-249
    • Lipinski, C.1
  • 6
    • 0031024171 scopus 로고    scopus 로고
    • Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
    • Lipinski C., et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Del. Revs. 23:1997;3-25.
    • (1997) Adv. Drug Del. Revs. , vol.23 , pp. 3-25
    • Lipinski, C.1
  • 7
    • 0037468884 scopus 로고    scopus 로고
    • A comparison of physiochemical property profiles of development and marketed oral drugs
    • Wenlock M.C., et al. A comparison of physiochemical property profiles of development and marketed oral drugs. J. Med. Chem. 46:2003;1250-1256.
    • (2003) J. Med. Chem. , vol.46 , pp. 1250-1256
    • Wenlock, M.C.1
  • 8
    • 0037566356 scopus 로고    scopus 로고
    • Examination of the computed molecular properties of compounds selected for clinical development
    • Blake J.F. Examination of the computed molecular properties of compounds selected for clinical development. BioTechniques. 34:2003;S16-S20.
    • (2003) BioTechniques , vol.34
    • Blake, J.F.1
  • 9
    • 0032872173 scopus 로고    scopus 로고
    • How many leads from HTS?
    • Lahana R. How many leads from HTS? Drug Disc. Today. 4:1999;447-448.
    • (1999) Drug Disc. Today , vol.4 , pp. 447-448
    • Lahana, R.1
  • 10
    • 0021745755 scopus 로고
    • Functional group contributions to drug-receptor interactions
    • Andrews P., et al. Functional group contributions to drug-receptor interactions. J. Med. Chem. 27:1984;1648-1657.
    • (1984) J. Med. Chem. , vol.27 , pp. 1648-1657
    • Andrews, P.1
  • 11
    • 0033621044 scopus 로고    scopus 로고
    • The maximal affinity of ligands
    • Kuntz I., et al. The maximal affinity of ligands. Proc. Natl. Acad. Sci. U. S. A. 96:1999;9997-10002.
    • (1999) Proc. Natl. Acad. Sci. U. S. A. , vol.96 , pp. 9997-10002
    • Kuntz, I.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.